Clinical Trials

Find a Trial

Trial Results

58 protocol(s) meet the specified criteria
9812-11OPEN TO ACCRUAL
Laboratory Studies of Peripheral Blood and Bone Marrow Cells Isolated from Patients with Clonal Myeloid or Lymphoproliferative Disorders
A011104OPEN TO ACCRUAL
Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer
A011202OPEN TO ACCRUAL
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A011401OPEN TO ACCRUAL
RANDOMIZED PHASE III TRIAL EVALUATING THE ROLE OF WEIGHT LOSS IN ADJUVANT TREATMENT OF OVERWEIGHT AND OBESE WOMEN WITH EARLY BREAST CANCER
A011502OPEN TO ACCRUAL
A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR NODE POSTIVE HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL
A081105OPEN TO ACCRUAL
RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF ERLOTINIB OR PLACEBO IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
A151216OPEN TO ACCRUAL
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
A221405/IBCSG48-POSITIVEOPEN TO ACCRUAL
A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy(POSITIVE)
ARRAY818-302OPEN TO ACCRUAL
The BEACON CRC Study (Binimetinib, Encorafenib, And Cetuximab COmbiNed to Treat BRAF-mutant ColoRectal Cancer): A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer
BBI608-201OPEN TO ACCRUAL
A Phase Ib/II Clinical Study of BBI608 Administered with Paclitaxel in Adult Patients with Advanced Malignancies
BR-076OPEN TO ACCRUAL
A Randomized Phase II clinical trial assessing the Efficacy and Safety of MK-3475 ( pembrolizumab) in combination with carboplatin and gemcitabine in patients with metastatic triple negative breast cancer
BRE12-158OPEN TO ACCRUAL
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer
BTCRC-GI13-002OPEN TO ACCRUAL
An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients with Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002
BTCRC-LUN16-081OPEN TO ACCRUAL
Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
BTCRCLUN15-029OPEN TO ACCRUAL
A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor
C16-168OPEN TO ACCRUAL
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects
CANSTEM111POPEN TO ACCRUAL
A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma.
CP-MGAH22-04OPEN TO ACCRUAL
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
E1Z11OPEN TO ACCRUAL
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
E2112OPEN TO ACCRUAL
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer
E4512OPEN TO ACCRUAL
A Phase III Double Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
EA5142OPEN TO ACCRUAL
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) ? A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
EAY131-C1/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
EAY131-C2/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
EAY131-L/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
EAY131-M/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
EAY131-Z1C/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
EAY131-Z1E/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
EAY131/MATCHOPEN TO ACCRUAL
Molecular Analysis for Therapy Choice (MATCH)
GU115/I6A-MC-CBBDOPEN TO ACCRUAL
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer
GU14-188OPEN TO ACCRUAL
Phase Ib/II Study of Neoadjuvant Pembrolizumab (MK-3475) with Gemcitabine-Cisplatin (cisplatin eligible) or Gemcitabine (cisplatin-ineligible) in Subjects with T2-4aN0M0 Urothelial Cancer
IUCRO-0031OPEN TO ACCRUAL
Molecular and Pathological Correlates of Treatment Outcome in Patients with Thymoma and Thymic Carcinoma
IUCRO-0049OPEN TO ACCRUAL
Immunologic, Genetic, Molecular, and Pathological Correlates with Clinical and Treatment Outcome in Patients with Renal Cell Carcinoma
IUCRO-0216OPEN TO ACCRUAL
Indiana University Simon Cancer Center Hematologic Malignancies Tissue Bank
IUCRO-0280OPEN TO ACCRUAL
IU Simon Cancer Center Tissue Bank
IUCRO-0454OPEN TO ACCRUAL
Molecular Phenotyping of Pancreatic Cancer Cachexia: A Bridge to Personalized Targeted Therapy
IUCRO-0486OPEN TO ACCRUAL
A Pilot Study Evaluating a Novel Biodynamic Imaging (BDI) Method in Predicating Response to Chemotherapy in Locoregional Esophageal Cancer
IUCRO-0514OPEN TO ACCRUAL
Collection Of Specimens And Clinical Data To Create A Biorepository For Metastatic Breast Cancer
IUSCC-0555OPEN TO ACCRUAL
Inhibiting fatty acid synthase to improve efficacy of neoadjuvant chemotherapy.
IUSCC-0590OPEN TO ACCRUAL
iMETX (Individualized Metabolic RX): a pilot study of an environmental intervention to increase energy expenditure among breast cancer survivors
IUSCC-0597OPEN TO ACCRUAL
A phase II trial of cabozantinib and erlotinib for patients with EGFR and c-Met co-expressing metastatic pancreatic adenocarcinoma
IUSCC-0612OPEN TO ACCRUAL
Mindfulness to Enhance Quality of Life and Support Advance Care Planning (MEANING): A Randomized Controlled Pilot Trial for Adults with Metastatic Cancer and Their Family Caregivers
IUSCC-0613OPEN TO ACCRUAL
An initial safety study of Gedatolisib plus PTK7-ADC for metastatic triple-negative breast cancer
IUSCC-0616OPEN TO ACCRUAL
A Prospective Feasibility Study Investigating Primary Preventive Ability of Massage Therapy of Paclitaxel-Induced Peripheral Neuropathy in Patients with Newly Diagnosed Breast Cancer Scheduled to Undergo a Paclitaxel Based Regimen
IUSCC-0617OPEN TO ACCRUAL
Examination of the informed consent process as experienced by patients who have undergone a chemoembolization, radioembolization or transjugular intrahepatic portosystemic shunt (TIPS) procedure
IUSCC-0625OPEN TO ACCRUAL
Computerized Cognitive Training in Breast Cancer Survivors
IUSCC-0632OPEN TO ACCRUAL
Pilot Study to Examine Correlation of Nab-Paclitaxel/Gemcitabine Pharmacokinetics with Cachexia
LCCC1317OPEN TO ACCRUAL
Genotype-directed Phase II Study of Irinotecan Dosing in Metastatic Colorectal Cancer (mCRC) Patients Receiving FOLFIRI + Bevacizumab
NSABP-B-55/BIG6-13OPEN TO ACCRUAL
A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
PRE0109OPEN TO ACCRUAL
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer [AFT-05]
RADY-GU-SAYKIN-TLCOPEN TO ACCRUAL
Older Breast Cancer Patients: Risk for Cognitive Decline
S1416OPEN TO ACCRUAL
PHASE II RANDOMIZED PLACEBO-CONTROLLED TRIAL OF CISPLATIN WITH OR WITHOUT ABT-888 (VELIPARIB) IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER AND/OR BRCA MUTATION-ASSOCIATED BREAST CANCER
S1505OPEN TO ACCRUAL
A RANDOMIZED PHASE II STUDY OF PERIOPERATIVE mFOLFIRINOX VERSUS GEMCITABINE/NAB-PACLITAXEL AS THERAPY FOR RESECTABLE PANCREATIC ADENOCARCINOMA
S1609OPEN TO ACCRUAL
DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS
TBCRC034OPEN TO ACCRUAL
The incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in patients diagnosed with Flat Epithelial Atypia (FEA) or Intraductal Papilloma without Atypia (IPWA) by Core Needle Biopsy
TBCRC035OPEN TO ACCRUAL
Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II study with Pharmacodynamics Markers
TBCRC040OPEN TO ACCRUAL
Plasma Tumor DNA and Pathologic Complete Response in Early-Stage, High-Risk Breast Cancer
WO29636OPEN TO ACCRUAL
A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA AFTER SURGICAL RESECTION